What happened with BRKR today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Bruker supplies tools that help researchers understand molecules, laboratories identify microorganisms, and manufacturers analyze materials. Universities, government laboratories, pharmaceutical and biotechnology companies, hospitals and industrial businesses pay for its instruments, software and supporting services. For example, its MALDI BioTyper identifies microorganisms for clinical laboratories. Scientific instruments and analytical and diagnostic solutions account for most of the business; services and aftermarket support also generate revenue.
A smaller business, Bruker Energy & Supercon Technologies (BEST), sells superconducting materials used in magnetic resonance imaging and research instruments, as well as fusion-energy and high-energy-physics research.
Bruker does not depend on a single customer, but many purchases depend on research budgets and funding for expensive equipment. Government-supported research is particularly important to its U.S. sales, while government stimulus programs fund a significant part of its China sales. Complex systems can take a long time to sell and deliver because of customer budgeting, customization and installation readiness. Production also relies on a limited number of suppliers for some components. Clinical products must meet medical-device requirements in the markets where they are sold, and export controls and sanctions can restrict shipments.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Agilent and Bruker compete for life-science and applied laboratories’ spending on instruments that identify and measure molecules, including mass spectrometry and spectroscopy systems. Watch Agilent’s instrument sales rather than CrossLab consumables, which it can sell regardless of whose instruments a laboratory uses.
Thermo Fisher Scientific competes with Bruker for research and industrial customers buying instruments for molecular and materials analysis, including mass spectrometry and molecular spectroscopy. Its Analytical Instruments business is the part to watch for this overlap, rather than its broader laboratory products and pharmaceutical services.
Waters competes with Bruker to sell research and applied laboratories mass spectrometry systems for molecular analysis. Separate new instrument sales from service and support: the latter accounted for over 35% of Waters’ sales in 2025 and includes maintenance and repairs.
Danaher challenges Bruker in instruments that research laboratories use to analyze molecules and view samples: its SCIEX business competes in mass spectrometry and Leica in microscopy. News from those businesses is more directly relevant to Bruker than Danaher’s broader Biotechnology and Diagnostics operations.
10x Genomics, Inc. competes with Bruker for academic and biopharmaceutical researchers buying tools to analyze individual cells and their positions in tissue, while Bruker also owes it royalties under their patent settlement. Its royalties on covered Bruker product and service sales create a direct financial link alongside competition from Chromium, Visium and Xenium.
Bio-Techne competes with Bruker to supply research and biopharmaceutical laboratories with spatial-biology and biological-analysis tools. Watch its spatial-biology business specifically; its larger Protein Sciences segment also sells reagents and analytical solutions, so company-wide sales cover more than this overlap.
Revvity and Bruker depend on overlapping academic and drug-discovery budgets: Revvity sells cell, gene and protein research tools, while Bruker sells instruments for biological analysis. Revvity’s Life Sciences sales to academic institutions and pharmaceutical and biotechnology customers are the relevant signal, rather than its Diagnostics business.
Bio-Rad and Bruker draw on the same research and biopharmaceutical laboratory budgets for instruments and related products used to analyze biological materials. Watch Bio-Rad’s Life Science segment, which generated approximately 40% of consolidated net sales in 2025, rather than treating its larger Clinical Diagnostics business as a read-through to Bruker.
Mettler-Toledo and Bruker both depend on life-science, chemical and food customers buying laboratory instruments for research and quality control. Mettler-Toledo’s laboratory instruments and related services, approximately 56% of net sales in 2025, are the revenue line to watch for that shared spending.
AMETEK’s Spectro and Edax divisions compete with Bruker to supply materials-analysis instruments to research and industrial customers. Those businesses sit within AMETEK’s electronic-instrument offering; its motion-control, medical-component and other electromechanical businesses are outside this tie.
Quanterix Corporation’s expanded spatial-biology business competes with Bruker for research laboratories’ instrument and consumable purchases. Watch that business separately from its Simoa tools, which detect very low concentrations of proteins in blood and other fluids.
Standard BioTools Inc.’s retained cellular-analysis tools compete with Bruker’s spatial-biology and single-cell tools for purchases by academic and biopharmaceutical researchers. Watch its continuing mass cytometry and microfluidics businesses, including CyTOF instruments for measuring many cell markers, rather than the sold SomaScan business.
Danaher Corporation earningsDHR
Danaher’s report, especially its SCIEX mass spectrometry and Leica microscopy businesses, will show whether demand is holding up for instruments that compete with Bruker’s.
Focus on any demand commentary or sales trends for SCIEX and Leica, not Danaher’s company-wide results. Firm demand in those businesses would suggest laboratories are still buying mass spectrometers and microscopes that compete with Bruker’s; weaker demand could reflect tighter customer budgets or stronger competitive pressure on Bruker. The conclusion is whether the instrument markets Bruker serves have support.
Bruker Corporation earningsThis company
Bruker’s report will show whether research and industrial customers are buying more instruments and whether tariffs and other costs are still squeezing margins on those sales.
Read organic revenue growth alongside gross margin; organic revenue excludes the effects of acquisitions and currency movements. Growth with a steady margin would suggest customer purchases are recovering without further cost pressure. Flat or falling revenue with a lower margin would show that delayed research-equipment purchases and higher costs are still weighing on Bruker. The conclusion is whether demand is improving and margins can hold up.
Revvity, Inc. earningsRVTY
Revvity’s Life Sciences sales to academic, pharmaceutical, and biotechnology customers will show whether those customers are still spending from budgets that Bruker also depends on.
Focus on Revvity’s Life Sciences sales to academic, pharmaceutical, and biotechnology customers, rather than its Diagnostics business. Stronger sales would suggest those customers’ research budgets are still flowing, supporting purchases that may include Bruker’s biological-analysis instruments; weaker sales would point to tighter spending by shared customers, though the companies sell different products. The conclusion is whether those research budgets are supporting Bruker’s customers.
10x Genomics, Inc. earningsTXG
10x Genomics’ royalty revenue can offer a read-through to sales of some Bruker products and services, while also reflecting the royalty cost tied to them.
Look for 10x Genomics’ reported royalty revenue and any detail on which Bruker products or services it covers. Higher royalties on a comparable basis would be consistent with more sales of covered Bruker offerings, but would also mean higher royalty costs; lower royalties could indicate fewer covered sales, though product mix and timing may affect the figures. The conclusion is whether this sales signal and the associated licensing cost are both rising.
